Abstract: In at least one embodiment, a road alert system is provided. The system includes a loudspeaker array and at least one controller. The loudspeaker array transmits an audio output signal to a vehicle traveling on a road. The at least one controller is programmed to receive a message indicative of a warning for the vehicle for transmission on the audio output signal and to apply equalization parameters to the message to increase in-vehicle speech intelligibility of the audio output signal within the vehicle. The at least one controller is further programmed to transmit the audio output signal via the loudspeaker array in a beamforming mode to minimize noise pollution for objects positioned along the road.

Abstract: Techniques for measuring fluid properties include circulating a mixed-phase fluid flow through a fluid flow circuit; circulating the mixed-phase fluid flow through a pre-polarizing magnet; polarizing at least a gas phase of the mixed-phase fluid flow to an initial polarization; measuring fluid induction decay (FID) values of the polarized gas phase with the EFNMR detector; determining a velocity of the gas phase based on the FID values of the polarized gas phase; producing a pulsed magnetic field gradient to suppress one or more signals acquired by the EFNMR detector with a first electromagnet; measuring FID values of the liquid phase of the mixed-phase fluid with the EFNMR detector simultaneously with the production of the pulsed magnetic field gradient; producing a homogeneous polarizing field to polarize the liquid phase of the mixed-phase fluid with a second electromagnet; and determining a velocity and content of the liquid phase based on the FID values of the polarized liquid phase.

Abstract: Techniques for measuring liquid properties include circulating a mixed oil-water liquid flow through a fluid flow circuit; polarizing the mixed oil-water liquid flow with a pre-polarizing magnet to an initial polarization; circulating the polarized mixed oil-water liquid flow to an EFNMR detector that includes a radio-frequency (RF) coil and a surrounding electromagnet; further polarizing the polarized mixed oil-water liquid flow with the surrounding electromagnet; measuring fluid induction decay (FID) values of the additionally polarized mixed oil-water liquid flow with the EFNMR detector; transforming the measured FID values to an effective adiabatic transition from the Earth's field to the polarizing field; determining a velocity of the oil in the mixed oil-water liquid flow and a velocity of the water in the mixed oil-water liquid flow based on differences in NMR signal relaxation properties of the transformed FID values; and determining an oil content and a water content of the mixed oil-water liquid flo

Abstract: Provided herein are compositions, methods and uses involving antibodies that specifically bind to Axl, a receptor tyrosine kinase. Also provided are uses and methods for managing, treating, or preventing disorders, such as cancer using the anti-Axl antibodies.

Abstract: Techniques for measuring liquid properties include circulating a mixed oil-water liquid flow through a fluid flow circuit; polarizing the mixed oil-water liquid flow with a pre-polarizing magnet to an initial polarization; circulating the polarized mixed oil-water liquid flow to an EFNMR detector that includes a radio-frequency (RF) coil and a surrounding electromagnet; further polarizing the polarized mixed oil-water liquid flow with the surrounding electromagnet; measuring fluid induction decay (FID) values of the additionally polarized mixed oil-water liquid flow with the EFNMR detector; transforming the measured FID values to an effective adiabatic transition from the Earth's field to the polarizing field; determining a velocity of the oil in the mixed oil-water liquid flow and a velocity of the water in the mixed oil-water liquid flow based on differences in NMR signal relaxation properties of the transformed FID values; and determining an oil content and a water content of the mixed oil-water liquid flo

Abstract: Techniques for measuring fluid properties include circulating a mixed-phase fluid flow through a fluid flow circuit; circulating the mixed-phase fluid flow through a pre-polarizing magnet; polarizing at least a gas phase of the mixed-phase fluid flow to an initial polarization; measuring fluid induction decay (FID) values of the polarized gas phase with the EFNMR detector; determining a velocity of the gas phase based on the FID values of the polarized gas phase; producing a pulsed magnetic field gradient to suppress one or more signals acquired by the EFNMR detector with a first electromagnet; measuring FID values of the liquid phase of the mixed-phase fluid with the EFNMR detector simultaneously with the production of the pulsed magnetic field gradient; producing a homogeneous polarizing field to polarize the liquid phase of the mixed-phase fluid with a second electromagnet; and determining a velocity and content of the liquid phase based on the FID values of the polarized liquid phase.

Abstract: The invention is directed, in part, to a system or method for validating identification cards of a person using the card to establish their identity or age so as to be allowed to enter a facility, purchase a product; or participate in a service. In an example, the validation relates to whether a person can purchase or consume alcohol, the system comprising: scanning the identification card, review of information on the identification card; evaluating the age on the identification card; wherein the age on the identification card is used to establish whether a person with the identity card is eligible to purchase and consume alcohol.

Abstract: The present invention is directed to compounds, tautomers and pharmaceutically acceptable salts of the compounds which are disclosed, wherein the compounds have the structure of Formula I, wherein the variables R1, R2, R3, R4 and X are as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

Abstract: The present invention is directed to compounds, tautomers and pharmaceutically acceptable salts of the compounds which are disclosed, wherein the compounds have the structure of Formula I, and the variables R1, R2 and R3 are as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

Abstract: The present invention is directed to compounds, tautomers and pharmaceutically acceptable salts of the compounds which are disclosed, wherein the compounds have the structure of Formula I, and the variable R1 is as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

Abstract: The present invention is directed to compounds, tautomers and pharmaceutically acceptable salts of the compounds which are disclosed, wherein the compounds have the structure of Formula I, wherein the variables R1, R2, R3, R4 and X are as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

Abstract: The present invention is directed to compounds, tautomers and pharmaceutically acceptable salts of the compounds which are disclosed, wherein the compounds have the structure of Formula I, and the variables R1, R2 and R3 are as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

Abstract: The present invention is directed to compounds, tautomers and pharmaceutically acceptable salts of the compounds which are disclosed, wherein the compounds have the structure of Formula I, and the variable R1 is as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

Abstract: The present invention is directed to compounds, tautomers and pharmaceutically acceptable salts of the compounds which are disclosed, wherein the compounds have the structure of Formula I, wherein the variables R1, R2, R3, R4 and X are as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

Abstract: The present invention is directed to compounds, tautomers and pharmaceutically acceptable salts of the compounds which are disclosed, wherein the compounds have the structure of Formula I, and the variables R1, R2 and R3 are as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

Abstract: The present invention is directed to compounds, tautomers and pharmaceutically acceptable salts of the compounds which are disclosed, wherein the compounds have the structure of Formula I, and the variable R1 is as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

Abstract: The present invention is directed to compounds, tautomers and pharmaceutically acceptable salts of the compounds which are disclosed, wherein the compounds have the structure of Formula I, and the variable R1 is as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

Abstract: The present invention is directed to compounds, tautomers and pharmaceutically acceptable salts of the compounds which are disclosed, wherein the compounds have the structure of Formula I, wherein the variables R1, R2 and R3 are as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

Abstract: The present invention is directed to compounds, tautomers and pharmaceutically acceptable salts of the compounds which are disclosed, wherein the compounds have the structure of Formula I, wherein the variables R1, R2 and R3 are as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

Abstract: The present invention is directed to compounds, tautomers and pharmaceutically acceptable salts of the compounds which are disclosed, wherein the compounds have the structure of Formula I, and the variables R1, R2 and R3 are as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.